AXGN:NSD-AxoGen, Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 19.85

Change

0.00 (0.00)%

Market Cap

USD 0.81B

Volume

0.11M

Avg Analyst Target

USD 24.75 (+24.69%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-24 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

N/A

USD50.51B 110.75 75.87
PODD Insulet Corporation

N/A

USD18.95B 2,177.56 158.14
ABMD Abiomed, Inc

N/A

USD14.90B 66.50 53.94
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

N/A

USD12.48B 62.34 30.81
TNDM Tandem Diabetes Care, Inc

N/A

USD6.52B N/A N/A
SWAV ShockWave Medical, Inc

N/A

USD6.07B N/A N/A
IART Integra LifeSciences Holdings ..

N/A

USD5.79B 34.37 20.57
INMD InMode Ltd

N/A

USD4.19B 48.60 39.99
LIVN LivaNova PLC

N/A

USD4.05B 77.40 N/A

ETFs Containing AXGN

Symbol Name Weight Mer Price(Change) Market Cap
HTEC Robo Global Healthcare Te.. 0.00 % 0.68 %

N/A

USD0.24B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.89% 47% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.89% 47% F 55% F
Trailing 12 Months  
Capital Gain 68.79% 60% D- 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 68.79% 60% D- 73% C
Trailing 5 Years  
Capital Gain 205.86% 79% C+ 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 205.86% 79% C+ 82% B-
Average Annual (5 Year Horizon)  
Capital Gain 48.20% 76% C 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 48.20% 76% C 84% B
Risk Return Profile  
Volatility (Standard Deviation) 103.56% 24% F 15% F
Risk Adjusted Return 46.54% 63% D 65% D
Market Capitalization 0.81B 66% D 62% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.74 35% F 22% F
Price / Cash Flow Ratio -84.55 91% A- 90% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -18.25% 69% D+ 42% F
Return on Invested Capital -14.84% 64% D 30% F
Return on Assets -7.32% 66% D 31% F
Debt to Equity Ratio 42.96% 51% F 43% F
Technical Ratios  
Short Ratio 7.47 18% F 12% F
Short Percent 3.98% 46% F 43% F
Beta 0.71 73% C 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector